Scilex Holding Company Repayments of Debt
Scilex Holding Company (SCLX) reported Repayments of Debt of $6.32 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfDebt · last filed 2026-08-14
- Scilex Holding Company repayments of debt for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Scilex Holding Company repayments of debt for the quarter ending 2026-03-31 was $6.32M.
- Scilex Holding Company repayments of debt for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Scilex Holding Company repayments of debt for the quarter ending 2025-09-30 was -$8.87M, a 622.00% decline year-over-year.
- Scilex Holding Company repayments of debt for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Scilex Holding Company repayments of debt for fiscal 2024 was $64.20M, a 1184.00% increase from fiscal 2023.
- Scilex Holding Company repayments of debt for fiscal 2023 was $5.00M.
| Period end | Repayments of Debt 3 month | Repayments of Debt 6 month | Repayments of Debt 6 month as first filed | Repayments of Debt 9 month | Repayments of Debt 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $6.32M 10-Q · filed 2026-08-14 | $6.32M derived: sum of 3 quarters · filed 2026-08-14 | -$2.56M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | $6.32M 10-Q · filed 2026-05-20 | $6.32M derived: sum of 2 quarters · filed 2026-05-20 | -$2.56M derived: sum of 3 quarters · filed 2026-05-20 | $6.32M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | -$8.87M derived: sum of 2 quarters · filed 2026-04-10 | $0.00 derived: sum of 3 quarters · filed 2026-08-14 | $0.00 10-K · filed 2026-04-10 | |
| 2025-09-30 | -$8.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $0.00 derived: sum of 2 quarters · filed 2026-08-14 | $0.00 10-Q · filed 2025-11-14 | $27.50M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | $8.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $8.87M 10-Q · filed 2026-08-14 | $0.00 10-Q · filed 2025-08-13 | $36.37M derived: sum of 3 quarters · filed 2026-08-14 | $38.07M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-20 | $27.50M derived: sum of 2 quarters · filed 2026-05-20 | $29.20M derived: sum of 3 quarters · filed 2026-05-20 | $49.20M derived: sum of 4 quarters · filed 2026-05-20 | |
| 2024-12-31 | $27.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $29.20M derived: sum of 2 quarters · filed 2026-04-10 | $49.20M derived: sum of 3 quarters · filed 2026-04-10 | $64.20M 10-K · filed 2026-04-10 | |
| 2024-09-30 | $1.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $21.70M derived: sum of 2 quarters · filed 2025-11-14 | $36.70M 10-Q · filed 2025-11-14 | $41.70M derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | $20.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $35.00M 10-Q · filed 2025-08-13 | $40.00M derived: sum of 3 quarters · filed 2025-08-13 | $40.00M derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $15.00M 10-Q · filed 2025-05-14 | $20.00M derived: sum of 2 quarters · filed 2025-05-14 | $20.00M derived: sum of 3 quarters · filed 2025-05-14 | $20.00M derived: sum of 4 quarters · filed 2025-05-14 | |
| 2023-12-31 | $5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $5.00M derived: sum of 2 quarters · filed 2025-03-31 | $5.00M derived: sum of 3 quarters · filed 2025-03-31 | $5.00M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-01-17 | $0.00 derived: sum of 2 quarters · filed 2025-01-17 | $0.00 10-Q · filed 2025-01-17 | ||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $0.00 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |